In Vivo Ocular Angiogenesis Assay

体内眼部血管生成测定

基本信息

批准号：
7218516
负责人：
WEN L SENG
金额：
$ 20.2万
依托单位：
PHYLONIX PHARMACEUTICALS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-05-01 至 2010-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7218516
关键词：
Adult Affect Age related macular degeneration Angiogenesis Inhibitors Animal Model Animal Testing Antibodies Biological Assay Biological Products Blindness Blood Vessels Caliber Clinical Services Clinical Trials Condition Contracts Cornea Corneal Neovascularization Deposition Development Developmental Delay Disorders Diabetic Retinopathy Disease Dose Embryo Employee Strikes End Point Enzymes Evaluation Extravasation Eye Fertilization Germany Government Hour Human Immunohistochemistry Infection Injury Invasive Label Lead Length Libraries Link Mammals Measurement Mediating Modeling Newborn Infant Operative Surgical Procedures Ophthalmic examination and evaluation Oxygen Performance Persons Pharmaceutical Preparations Pharmacologic Substance Phase Preclinical Drug Evaluation Premature Infant Process Provider Purpose Rattus Reader Reading Research Retina Retinal Detachment Retinopathy of Prematurity Rivers Services Signal Transduction Staining method Stains Supplementation Therapeutic Time Vascular Diseases Vascular Endothelial Growth Factors Vision Visual Zebrafish angiogenesis base collagenase day drug testing improved in vivo neovascularization novel therapeutics ocular angiogenesis ocular neovascularization postnatal programs research clinical testing research study tumor

项目摘要

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Retinopathy of prematurity (ROP) is a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea. Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. Using zebra fish, Phase I research developed a micro plate assay for quantifying effects of angiogenic compounds on ocular neovascularization. Phase II research will perform a pilot screen of available commercially compounds and confirm positive "hits" identified in conventional animal models. Phase II research will further validate the utility of the zebra fish model for screening drugs for treating debilitating diseases involving neovascularization. By providing a quantitative in vivo assay for assessing drug effects on ocular neovascularization, the proposed zebra fish assay will facilitate development of therapeutic drugs for treating debilitating diseases involving neovascularization.

描述（由申请人提供）：糖尿病视网膜病变（DR）和年龄相关性黄斑变性（AMD）是工业化国家成年人失明的两个主要原因。这两种情况都涉及血管异常、新血管增殖和渗漏。早产儿视网膜病变（ROP）是产后靠吸氧维持的早产儿新生儿失明的主要原因。这种疾病涉及视网膜的强烈新生血管形成并导致视网膜脱离。失明的另一个原因是角膜新生血管形成，这通常是由角膜损伤和感染引起的。目前用于眼部新生血管形成的哺乳动物模型需要漫长、繁琐的手术操作，并且并不总能改善视力；另一种用于研究眼部新生血管形成过程和评估药物效果的快速、侵入性较小的动物模型将有助于新疗法的鉴定。第一阶段研究使用斑马鱼开发了一种微孔板测定法，用于量化血管生成化合物对眼部新生血管形成的影响。第二阶段研究将对可用的商业化合物进行试点筛选，并确认在传统动物模型中发现的积极“效果”。第二阶段研究将进一步验证斑马鱼模型在筛选治疗涉及新生血管形成的衰弱疾病的药物方面的效用。通过提供定量体内测定来评估药物对眼新生血管形成的影响，所提出的斑马鱼测定将促进治疗药物的开发，用于治疗涉及新生血管形成的衰弱性疾病。